Moderna stock heads into the open after a 1.9% Nasdaq gain
Published on 09/15/2026 at 07:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Moderna stock closed at USD 146.69 on the Nasdaq on September 14, 2026, rising 1.89% from the prior session. Per Nasdaq data reported by Yahoo Finance, the shares outperformed the tech-heavy Nasdaq Composite, which advanced roughly 1% the same day.
September 14, 2026 in numbers
Moderna Inc. (ISIN US60770K1034, Nasdaq: MRNA) saw its latest session on the Nasdaq end at USD 146.69 on September 14, 2026, up 1.89% from the previous close, according to a wrap from Yahoo Finance. The same report noted that Moderna shares outpaced the broader market, as the Nasdaq Composite index added about 1% on September 14, 2026.
Sentiment around the stock has been supported by growing attention to its oncology and vaccine portfolio. An analysis on September 14, 2026 highlighted how interim success in Moderna's cancer vaccine programs has strengthened the investment case, even as the author argued that the share price reaction had become stretched, as discussed by Seeking Alpha. In parallel, a sector piece on September 14, 2026 pointed out that Moderna has secured regulatory approval for an mRNA-based flu vaccine, underlining the company’s push to diversify beyond COVID-19, as reported by Ad-hoc-news.
Today’s factors to watch
Heading into today’s session on September 15, 2026, investors will continue to weigh recent commentary on Moderna’s oncology prospects and vaccine pipeline. At the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026, company executives emphasized a reshaped strategy that balances a growing oncology pipeline with a broader vaccine franchise, according to Investing.com. Broader market conditions may also play a role, with recent coverage highlighting investor focus on interest-rate expectations and sector rotations within growth and healthcare names, as noted by CNBC. While Moderna’s next earnings release is projected for November 5, 2026, based on consensus calendars such as Zacks, today’s trading will mainly reflect ongoing reactions to its recent trial updates, regulatory milestones and the evolving macro backdrop.
